🐦 推特Wall St EngineCodex · 实盘不做把握 5/10
北京时间·🕒 发布 19:20:24时区推断·⟳ 抓取 19:20:46·⚡ 决策 07-28 19:24:32 +3m46s·91.0 天前
Incyte 二季度业绩大幅超预期，但全年收入指引低于市场预期且费用上调
二季度收入 16.7 亿美元、调整后 EPS 3.09 美元均明显高于市场预期，Opzelura 销售高增是主要正面增量。
📄 原文Wall St Engine@wallstengine↗ 原文
$INCY Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $1.67B (Est. $1.47B) 🟢; +38% YoY 🔹 Adj. EPS: $3.09 (Est. $2.10) 🟢 🔹 Opzelura…
不做 Incyte（INCY.US）
财报信号正负混合：Q2 beat 与 Opzelura 高增利好，但全年收入指引低于一致预期、费用上调且股价已近高位，盘前反应也未确认单边方向，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司提前公告 Q2 财报将在 2026-07-28 07:00 ET 发布，8:00 ET 召开电话会，财报日期本身已被市场预期。
- 社交账号在美股盘前转发 Q2 业绩摘要，显示收入和 EPS beat，但全年收入指引低于其列示的一致预期。市场反应:Investing.com 显示 INCY.US 盘前约 118.05 美元，较前收小跌约 0.32%，未出现强单边确认。
关键理由
- 二季度收入 16.7 亿美元、调整后 EPS 3.09 美元均明显高于市场预期，Opzelura 销售高增是主要正面增量。
- 全年收入指引 51.3–52.6 亿美元虽较此前公司口径上修，但低于推文所列 57.1 亿美元一致预期，且 R&D+SG&A 费用指引上调，抵消短线追多逻辑。
- INCY.US 报告前已接近 52 周高位，盘前报价仅小幅下跌，说明市场暂未给出明确单边重定价。
主要风险
- 若 8:00 ET 电话会解释全年收入指引口径与一致预期不可比，盘前的负面解读可能被修正。
- 10 项 2026 下半年数据读出提供管线期权，但财报日交易窗口内无法量化为确定 EPS 增量。
原文全文
展开原文 · 822 字
$INCY Q2’26 EARNINGS HIGHLIGHTS
🔹 Revenue: $1.67B (Est. $1.47B) 🟢; +38% YoY
🔹 Adj. EPS: $3.09 (Est. $2.10) 🟢
🔹 Opzelura Net Sales: $450M; +173% YoY
🔹 Jakafi Net Sales: $817M; +7% YoY
FY26 Guide Raised:
🔹 Revenue: $5.13B-$5.26B (Est. $5.71B) 🔴
🔹 Opzelura Net Sales: $1.05B-$1.10B
🔹 Jakafi Net Sales: $3.22B-$3.27B; unchanged
🔹 R&D + SG&A Opex: $4.63B-$4.70B; raised
Other:
🔹 Cash & Marketable Securities: $4.5B
🔹 10 data readouts expected in 2H26
Comments:
🔸 “We also recently strengthened our Hematology franchise through the acquisition of latarcibart, a potentially transformative medicine for von Willebrand disease currently in Phase 3 development. With ten data readouts expected in the second half of 2026, alongside product launches through early next year, we are well positioned for our next phase of growth.”
🔹 Revenue: $1.67B (Est. $1.47B) 🟢; +38% YoY
🔹 Adj. EPS: $3.09 (Est. $2.10) 🟢
🔹 Opzelura Net Sales: $450M; +173% YoY
🔹 Jakafi Net Sales: $817M; +7% YoY
FY26 Guide Raised:
🔹 Revenue: $5.13B-$5.26B (Est. $5.71B) 🔴
🔹 Opzelura Net Sales: $1.05B-$1.10B
🔹 Jakafi Net Sales: $3.22B-$3.27B; unchanged
🔹 R&D + SG&A Opex: $4.63B-$4.70B; raised
Other:
🔹 Cash & Marketable Securities: $4.5B
🔹 10 data readouts expected in 2H26
Comments:
🔸 “We also recently strengthened our Hematology franchise through the acquisition of latarcibart, a potentially transformative medicine for von Willebrand disease currently in Phase 3 development. With ten data readouts expected in the second half of 2026, alongside product launches through early next year, we are well positioned for our next phase of growth.”
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。